Beijing Northland Biotech
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Hepatocyte growth factor (HGF)Gene therapy / editing | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $7.3M | — | $17M | $5.1M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $10M | $6.1M | — | $6.3M | report ↗ |
Beijing Northland Biotech reported revenue of $10.04M, up 19.0% YoY, R&D spend of $6.06M, and a quarterly net burn of $6.29M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text